The deal is sourced from a lengthy UK-style scheme document (a Rule 2.7 announcement format) filed as an 8-K exhibit, dated January 7, 2021, which includes formal recommendation language from the Oxford Immunotec board of directors.
An affiliate of Perella Weinberg UK Limited, operating under the Perella Weinberg Partners name, served as financial advisor to Oxford Immunotec, the target, per the filing: "An affiliate of Perella Weinberg UK Limited ("Perella Weinberg Partners") is acting as financial advisor to Oxford Immunotec." The document also notes that Perella Weinberg Partners advised the Oxford Immunotec directors specifically on the consideration to be received by shareholders, and that Guggenheim Partners is named alongside Perella Weinberg Partners in a consent-to-publication clause, suggesting Guggenheim may have held a related advisory or fairness role for Oxford Immunotec, though its precise function is not spelled out in the excerpt.
Covington & Burling LLP served as legal counsel to Oxford Immunotec. On the PerkinElmer side, Wilmer Cutler Pickering Hale and Dorr LLP advised on U.S. law matters and Hogan Lovells International LLP advised on English law matters, reflecting the cross-border scheme structure.
The reviewed excerpt did not disclose the aggregate or per-share deal value, nor the cash/stock consideration mix. The transaction was expected to close in the first half of calendar 2021, subject to Oxford Immunotec shareholder approval, UK court approval of the scheme, and other customary closing conditions.
Not disclosed: the headline transaction value, the per-ADS or per-share price, and the precise advisory split between Perella Weinberg Partners and Guggenheim Partners on the Oxford Immunotec side.